Fotin-Mleczek M - Search Results

1

mRNA mediates passive vaccination against infectious agents, toxins, and tumors.

Thran M, Mukherjee J, Pönisch M, Fiedler K, Thess A, Mui BL, Hope MJ, Tam YK, Horscroft N, Heidenreich R, Fotin-Mleczek M, Shoemaker CB, Schlake T. Thran M, et al. Among authors: fotin mleczek m. EMBO Mol Med. 2017 Oct;9(10):1434-1447. doi: 10.15252/emmm.201707678. EMBO Mol Med. 2017. PMID: 28794134 Free PMC article.

2

Developing mRNA-vaccine technologies.

Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Schlake T, et al. RNA Biol. 2012 Nov;9(11):1319-30. doi: 10.4161/rna.22269. Epub 2012 Oct 12. RNA Biol. 2012. PMID: 23064118 Free PMC article. Review.

3

Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals.

Thess A, Grund S, Mui BL, Hope MJ, Baumhof P, Fotin-Mleczek M, Schlake T. Thess A, et al. Mol Ther. 2015 Sep;23(9):1456-64. doi: 10.1038/mt.2015.103. Epub 2015 Jun 8. Mol Ther. 2015. PMID: 26050989 Free PMC article.

4

mRNA: A Novel Avenue to Antibody Therapy?

Schlake T, Thran M, Fiedler K, Heidenreich R, Petsch B, Fotin-Mleczek M. Schlake T, et al. Among authors: fotin mleczek m. Mol Ther. 2019 Apr 10;27(4):773-784. doi: 10.1016/j.ymthe.2019.03.002. Epub 2019 Mar 6. Mol Ther. 2019. PMID: 30885573 Free PMC article. Review.

5

Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect.

Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Thess A, Duchardt KM, Kallen KJ. Fotin-Mleczek M, et al. J Gene Med. 2012 Jun;14(6):428-39. doi: 10.1002/jgm.2605. J Gene Med. 2012. PMID: 22262664

6

A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines.

Kallen KJ, Heidenreich R, Schnee M, Petsch B, Schlake T, Thess A, Baumhof P, Scheel B, Koch SD, Fotin-Mleczek M. Kallen KJ, et al. Hum Vaccin Immunother. 2013 Oct;9(10):2263-76. doi: 10.4161/hv.25181. Epub 2013 Jun 4. Hum Vaccin Immunother. 2013. PMID: 23921513 Free PMC article. Review.

7

Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines.

Lutz J, Lazzaro S, Habbeddine M, Schmidt KE, Baumhof P, Mui BL, Tam YK, Madden TD, Hope MJ, Heidenreich R, Fotin-Mleczek M. Lutz J, et al. Among authors: fotin mleczek m. NPJ Vaccines. 2017 Oct 19;2:29. doi: 10.1038/s41541-017-0032-6. eCollection 2017. NPJ Vaccines. 2017. PMID: 29263884 Free PMC article.

8

mRNA-based vaccines synergize with radiation therapy to eradicate established tumors.

Fotin-Mleczek M, Zanzinger K, Heidenreich R, Lorenz C, Kowalczyk A, Kallen KJ, Huber SM. Fotin-Mleczek M, et al. Radiat Oncol. 2014 Aug 15;9:180. doi: 10.1186/1748-717X-9-180. Radiat Oncol. 2014. PMID: 25127546 Free PMC article.

9

Self-adjuvanted mRNA vaccines induce local innate immune responses that lead to a potent and boostable adaptive immunity.

Kowalczyk A, Doener F, Zanzinger K, Noth J, Baumhof P, Fotin-Mleczek M, Heidenreich R. Kowalczyk A, et al. Vaccine. 2016 Jul 19;34(33):3882-93. doi: 10.1016/j.vaccine.2016.05.046. Epub 2016 Jun 18. Vaccine. 2016. PMID: 27269061

10

Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response.

Edwards DK, Jasny E, Yoon H, Horscroft N, Schanen B, Geter T, Fotin-Mleczek M, Petsch B, Wittman V. Edwards DK, et al. J Transl Med. 2017 Jan 3;15(1):1. doi: 10.1186/s12967-016-1111-6. J Transl Med. 2017. PMID: 28049494 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page